Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGFRL1 | Q5TC84 | 4/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | CTSE | P14091 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | LIPE | Q05469 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL852258 | 0.87 | JAK2 (0.38) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL880907 | 0.73 | OGFRL1 (0.73) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL854261 | 0.72 | OPRM1 (0.40) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL853294 | 0.66 | OPRL1 (0.55) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL880915 | 0.66 | OGFRL1 (0.74) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL10289955 | 0.66 | OGFRL1 (0.74) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL10062597 | 0.66 | CTSD (0.47) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL15861263 | 0.64 | CTSD (0.48) | OPRL1CTSDCTSEBACE1GPR119 | |
| SCHEMBL2606281 | 0.64 | KCNH2 (0.58) | OPRM1OPRK1OPRL1GPR119 | |
| SCHEMBL7479526 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3564240-A1 | PIPERIDINE INTERMEDIATES | Purdue Pharma L.P. (US) | 2019-11-06 | — | — | EP | disclosed |
| US-9527840-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-3101018-A1 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma L.P. (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2433937-B1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | PURDUE PHARMA LP (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20160159785-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2016-06-09 | — | — | US | disclosed |
| US-9278967-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150141643-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2015-05-21 | — | — | US | disclosed |
| EP-2086958-B1 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8846929-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2433937-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2433935-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2433936-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159785-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | P2RX4, P2RX5, P2RX3 | OGFRL1 2120/4885OPRM1 25/4885OPRK1 6/4885 |
| US-20150141643-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | P2RX4, P2RX5, P2RX3 | OGFRL1 2120/4885OPRM1 25/4885OPRK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.